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Transplantation in end-stage pulmonary hypertension
(Third International Right Heart Failure Summit, part 3)
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and Division of Cardiovascular Medicine, Department of Medicine, Brigham and Women’s Hospital and Harvard Medical
School, Boston, Massachusetts, USA
Abstract: The Third International Right Heart Summit was organized for the purpose of bringing an in-
terdisciplinary group of expert physician-scientists together to promote dialogue involving emerging concepts
in the unique pathophysiology, clinical manifestation, and therapies of pulmonary vascular disease (PVD) and
right heart failure (RHF). This review summarizes key ideas addressed in the section of the seminar entitled
“Transplantation in End-Stage Pulmonary Hypertension.” The ﬁrst segment focused on paradigms of re-
covery for the failing right ventricle (RV) within the context of lung-alone versus dual-organ heart-lung trans-
plantation. The subsequent 2-part section was devoted to emerging concepts in RV salvage therapy. A pre-
sentation of evolving cell-based therapy for the reparation of diseased tissue was followed by a contemporary
perspective on the role of mechanical circulatory support in the setting of RV failure. The ﬁnal talk highlighted
cutting-edge research models utilizing stem cell biology to repair diseased tissue in end-stage lung disease—a
conceptualframework within which new therapies for PVD have potential toevolve.Together, these provocative
talks provided a novel outlook on how the treatment of PVD and RHF can be approached.
Keywords: pulmonary hypertension, pulmonary vasculature, right ventricle, right-heart failure,
transplantation.
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The Third International Right Heart Failure Summit
was held in Boston in the fall of 2013 for the purpose of
bringing an interdisciplinary group of expert physician-
scientists together to promote dialogue involving emerg-
ing concepts in the pathophysiology, clinical manifesta-
tion, and therapies of pulmonary vascular disease (PVD)
and right heart failure (RHF). Speciﬁc goals for the sym-
posium were to develop an integrative nomenclature that
standardizes and effectively captures right heart disease, to
present contemporary theories in the pathobiology and
hemodynamics of the right ventricular (RV)–pulmonary
vascular axis, and to discuss novel therapeutic approaches
that may be used in the treatment of patients with vari-
ous right heart syndromes. To cover these broad-ranging
topics, the symposium was organized into the following
3 sections: (1) Pulmonary Hypertension and the Right Ven-
tricle—Thinking Outside the Box, (2) Emerging Hemody-
namic Signatures of the Right Heart, and (3) Transplanta-
tion in End-Stage Pulmonary Hypertension. Key concepts
addressed in the third section of the summit are the focus
of this review.
COMPLEX DECISIONS IN RV RECOVERY:
LUNG OR HEART-LUNG TRANSPLANT
Dr. Philip Camp opened the second day’s lecture series
with a review of the epidemiology, indications, eligibility,
and outcomes for patients undergoing heart-lung trans-
plantation, as compared to lung transplantation alone.
Considerable advances in medical therapy and the ability
to follow patients over time have contributed to a decrease
in the acute need for heart-lung en bloc transplantation.
According to the International Society for Heart and Lung
Transplantation (ISHLT) registry, the number of heart-
lung transplants has indeed declined from 1990 to 2010,
with less than a third of these being performed for idio-
pathic pulmonary arterial hypertension (IPAH).
1,2 Selec-
tion criteria for lung and heart-lung transplant were re-
viewed, and it was emphasized that appropriate patient
identiﬁcation and transplant discussion must occur early
in the treatment process. Eligibility entails the absence of
signiﬁcant multisystem dysfunction, New York Heart As-
sociation class III or IV functional status, and failure of
medical therapies.
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States is determined by a scoring system known as the
lung allocation score, with groups A–D used to categorize
patients according to underlying pathology. Overall me-
dian wait time for lung transplantation is now 3.6 months.
Patients with PVD (group B) experience the longest wait
times, at a median of 9.7 months, compared to the 2.1-
month median wait time for patients with restrictive lung
disease patients (group D).
3
Whichtransplantis theoptimalchoice? Single-lung trans-
plantation for pulmonary hypertension (PH) has largely
been abandoned because of adverse postoperative outcomes,
including pulmonary edema, graft dysfunction, and need
for prolonged mechanical circulatory support (MCS) and
ventilation.
1,2 The gold-standard and most common sur-
gical treatment option is double lung transplantation,
which allows for lower rates of postoperative diffuse alve-
olar damage, delayed onset of bronchiolitis obliterans
syndrome (which may play a role in chronic rejection), im-
proved pulmonary vascular resistance (PVR), and sus-
tained improvement in RV ejection fraction (EF).
4,5 De-
spite these noted advances, survival for PH patients after
transplant remains suboptimal, with a median survival of
5 years. The early postoperative period (3–6 months) re-
mains the time of greatest vulnerability for IPAH pa-
tients; however, if survival is maintained beyond years 1–
3, long-term outcomes are superior to those for patients
with chronic obstructive pulmonary disease (COPD), sar-
coidosis, or idiopathic pulmonary ﬁbrosis (IPF) (Fig. 1).
1,2
Heart-lung transplantation remedies the scenario in
which a patient is deemed “too sick” for lung transplanta-
tion alone for fear of unrecoverable right ventricle (RV)
function. Though historic indications of congenital heart
disease and PH with poor RV function remain relevant,
contemporary candidates include patients inappropriate
for MCS bridging or who have suffered MCS-related com-
plications. The large dual-organ bloc is implanted with a
short ischemic time and naturally provides a matched car-
diopulmonary relationship. Wait times are increased, and
long-term survival is reportedly lower (64% at 1 year),
1,2
compared to those for lung transplant alone. These data
are not randomized, however, and may be a reﬂection of
pretransplant heart-lung patients being more critically ill,
with worse end-organ damage. Survival for PAH patients
undergoing heart-lung transplant is similar to patients
with congenital heart disease.
1
Despite increases in lung transplantation worldwide,
only a minority of these procedures are performed for PH
and RHF. Determining the optimal timing of transplanta-
tion for these patients remainschallenging.Eligibility often
follows only when right atrial pressures exceed 15 mmHg
and/or when the cardiac index is measured as less than
1.8 L/min/m
2 and patients are in cardiogenic shock, which
obviates MCS as a bridge to transplant and may increase
chances of adverse events after transplantation. Although
posttransplant survival has improved for PH patients, the
current allocation scoring system may place them at a dis-
advantage relative to other groups on the pretransplant wait
list.
6 Recent attention to this matter prompted a reevalua-
tion of predictors of mortality and wait times and may
lead to the incorporation of other factors that reﬂect heart
failure.
7 Dr. Camp concluded his presentation with a pro-
posed shift in the PH-RV treatment paradigm from “treat-
ing the failing organ to rescuing and resuscitating the
failing organ,” invoking reports of MCS used to salvage the
RV and lungs.
8 With extracorporeal life support, for exam-
ple, the RV may be allowed a chance to positively remodel,
which could lead to improved outcomes after transplant.
APPROACHES TO RV SALVAGE THERAPY,
PART 1: CELLS
The next segment was devoted to current evolving thera-
pies used to salvage RV function in the setting of end-
stage disease. In the ﬁrst talk, Dr. Aaron Waxman reviewed
the mechanisms of altered cellular metabolism in PVD
and RHF, providing the conceptual framework within
which cell-based therapies are developing to restore RV
function. He reminded the audience that the RV is the
key determinant of clinical presentation and survival in
patients with PH, rather than mean pulmonary arterial
pressure, which correlates poorly with patient symptoms.
9
Alterations in cellular metabolism
As PVR approaches systemic vascular resistance, ﬂow to
the RV may be impeded. Regional hypoxia develops in
the myocardium, which in turn results in alterations in
several downstream regulatory pathways, causing capil-
lary rarefaction and worsening hypoxia. As the hypoxia
progresses, decreased mitochondrial density is observed,
along with a shift in mitochondrial function from the
highly efﬁcient process of oxidative phosphorylation to
the less efﬁcient process of glycolysis. Speciﬁcally, the
combination of (1) decreased vascular endothelial growth
factor (VEGF) expression, (2) increased transcription of
glucose transporter 1, hexokinase, and lactate dehydroge-
nase kinase, which inhibit glucose oxidation, and (3) re-
duced coronary perfusion and capillary density results in
ischemia and drives the shift to glycolysis.
10-13 Work done
by Xu et al.,
14 as well as by Dr. Waxman’s group, has dem-
onstrated decreased mitochondrial dehydrogenase, num-
718 | Transplantation in end-stage PH Lalaber of mitochondria per cell, and mitochondrial DNA con-
tent in diseased PA endothelial cells, all of which im-
proved after exposure to nitric oxide donors. Similarly,
PA smooth muscle cells exhibited disordered mitochon-
drial metabolism and redox signaling, resulting in de-
creased oxygen extraction and production of adenosine
triphosphate (ATP). Patients with PAH and RHF have
increased oxygen requirements, lower oxygen extraction
reserve, and increased dependence on coronary blood
ﬂow.
15-18 Positron emission tomography imaging has been
used to demonstrate the shift to the energetically less fa-
vorable glycolysis, where increased 18-ﬂuorodeoxyglucose
uptake is seen in untreated PAH-induced RV hypertro-
phy.
19 The vicious cycle of RV failure ensues (Fig. 2),
17
with various potential targets for ameliorating RV function.
Stem cell therapy
Having outlined a comprehensive rationale, Dr. Wax-
man turned to the focus of his talk, cell-based therapy in
regenerative medicine. Conventional stem cell therapy is
thought to develop from totipotent stem cells, which have
the ability to differentiate into many different adult cell
types and form specialized tissue needed for embryonic
development. More pertinent approaches today involve
the use of pluripotent (plural) or multipotent (mature)
cells, which have potential to form differentiated adult
cell lines. There are essentially 2 types of stem cells: em-
bryonic stem cells, which are received from aborted em-
bryos created via in vitro fertilization, and adult stem
cells, which are received from limited tissues, namely,
bone marrow, muscle, and brain, but also from the pla-
cental cord and baby teeth. Stem cells exist in micro-
environments called “niches,” where they are in direct
contact with and exposed to soluble factors that provide
support and signals regulating self-renewal and differ-
entiation. Depending on what kind of environment they
are nurtured in, there is a tendency to generate cell types
of the tissue in which they reside. Recent experiments
have raised the possibility of stem cells from one tissue
giving rise to other cell types, forming the basis of a con-
cept known as plasticity.
Cell-based therapy can be used to repair, regenerate, or
replace damaged organs. For the purposes of treating pa-
tients with RHF and PVD, the hope is to stimulate tissue
at the cellular and molecular level to repair itself. In work
by Dr. Duncan Stewart’s group,
20 bone marrow–derived
endothelial progenitor cells (EPCs), which function to re-
pair and regenerate blood vessels, as well as endothelial
nitric oxide synthatase (eNOS)–engineered EPCs, were
used to prevent injury and restore microvasculature struc-
Figure 1. Kaplan-Meier survival by diagnosis for adult lung transplants performed between January 1990 and June 2010, condi-
tioned on surviving to 1 year. Among patients surviving at least 1 year, there were better conditional half-lives after transplant
for diagnoses of CF (10.4 years), PAH (10.0 years), sarcoidosis (8.4 years), and Alpha-1 (8.6 years) than for diagnoses of COPD or
IPF (6.8 years for both). Alpha-1: α1-antitrypsin deﬁciency emphysema; CF: cystic ﬁbrosis; COPD: chronic obstructive pulmonary
disease; IPF: idiopathic pulmonary ﬁbrosis; PAH: pulmonary arterial hypertension. Reproduced with permission from Figure 18
of Christie et al.
1
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lative survival was improved most with eNOS-engineered
EPCs, followed by regular EPCs, compared to controls,
in the setting of monocrotaline-induced lung injury.
20
Dr. Waxman expressed the increased facility of using
mesenchymal stem cells (MSCs), which are easier to iso-
late and can be obtained from cord, fat, and bone mar-
row.
21,22 They have paracrine and angiogenic properties,
which include the secretion of growth factors (VEGF, ﬁ-
broblast growth factor, and hepatocyte growth factor) and
stimulation of endothelial cell proliferation. These cells
also have anti-inﬂammatory properties, conferring the in-
hibition of T cell proliferation, downregulation of proin-
ﬂammatory factor secretion, and reduction of oxidative
stress and endothelial damage, as seen in murine models
of hind-limb ischemia.
23 MSCs can repair a variety of tis-
sues after injury and are currently being used in clinical
trials to treat patients with cardiovascular disease. The pre-
cise mechanism of action and the role of myocyte regener-
ation versus angiogenesis, however, are controversial.
24-27
In a canine model of anterior infarction and chronic ische-
mia, large numbers of MSCs were infused without caus-
ing damage. In fact, MSCs differentiated into smooth
muscle cells and endothelial cells, resulting in signiﬁcant
left ventricular EF improvement at 60 days and a trend
toward reduced ﬁbrosis and greater vascular density.
28
Understanding possible mechanisms by which stem
cells restore function compels returning to the essential
Figure 2. Cycle of right ventricular (RV) failure. Reduced RCA ﬂow and RCA systolic perfusion pressure in RVH are ultimately
unable to support the increased oxygen demand of increased RV mass. This leads to RV hypoxia and ischemia. Transcriptional
factors (HIF-1α and Myc) are activated by RV ischemia, which contributes to a switch from mitochondrial metabolism (glucose
oxidation) to glycolysis. RV function is then further reduced by the depressed ATP production and myocardial acidosis, leading to
RV failure as a part of a continuous cycle. BNP: brain natriuretic peptide; CO: cardiac output; Glut-1: glucose transporter 1; HIF-
1α: hypoxia-induced factor-1α; PCr: phosphocreatine; PDH: pyruvate dehydrogenase; PDK: pyruvate dehydrogenase kinase; RCA:
right coronary artery; RVH: RV hypertrophy. Adapted, with kind permission of Springer Science+Business Media, from Figure 1 of
Piao et al.
17
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the regulation of metabolism and energy production but
also control of stress responses, apoptosis, necrosis, and
organ hibernation.
29-31 When healthy MSCs are mixed
with vascular stem cells, they bridge to one another with
nanotubes wherein the transfer of functional mitochon-
dria can be observed.
32 Spees et al.
33 demonstrated this
process by using a lung cancer cell line called A549 cells;
they rendered mitochondria is this line dysfunctional, so
that they no longer were able to generate substantial
ATP. After these cells were mixed with MSCs, the for-
mation of nanotubes was observed, enabling transfer of
healthy mitochondria to diseased cells and restoration of
A549 cells’ ability to generate increased ATP.
33 Similarly, a
protective murine model showed mitochondrial transfer
from healthy bone marrow–derived stromal cells (BMSCs)
to pulmonary alveoli in lipopolysaccharide-induced lung
injury. Lung injury, as indicated by protein leak and leu-
kocytosis, was retracted, and increased ATP generation
was observed with transfer of healthy mitochondria from
BMSCs.
34 Although mitochondrial transfer has been dem-
onstratedas such in vitro,it is unclear whether this occurs
in vivo.
Dr. Waxman concluded the presentation by sharing a
swine model developed in his laboratory to study this
paradigm. Injection of amide-coated glass beads was used
to provide for an inﬂammatory response and obstruc-
tive vasculopathy–induced RHF, deﬁned as a decrease
in cardiac output by 35%, a decrease in PO2 to less than
70 mmHg, and RV hypertrophy. This model allows for
stem cell therapy delivery directly via the right coronary
artery and assessment of its effect on right-heart response
over time. Questions that remain in this emerging ﬁeld
include, but are not limited to, the following: (1) What
is the mode of action by which mitochondria improve
function? (2) What is the fate of these stem cells? (3) Can
these cells migrate to nontarget sites? (4) Is there poten-
tial for uncontrolled cell proliferation or tumorigenicity?
(5) Are there potential graft-versus-host effects that can
ensue? The goal of this science will be the translation of
therapy to clinical practice, to potentially allow for alter-
native means of rescue therapy and bridging to trans-
plantation for patients with RHF in the setting of end-
stage PVD.
APPROACHES TO RV SALVAGE THERAPY,
PART 2: MACHINES
Dr. Francis Pagani delivered the second half of this
2-part segment by providing an experienced surgeon’s
insight into the perhaps more commonly employed sal-
vage therapy, MCS. Optimal timing for initiation of MCS
is vital to ensure favorable outcomes and is based on a
number of variables: the level of and response to medical
support, hemodynamics, end-organ perfusion, past his-
tory, transplant status, and institutional experience with
various MCS devices, among others. In addition to tim-
ing, several important questions warrant careful consid-
eration to determine appropriate MCS selection: (1) Does
the patient require partial, versus full, hemodynamic sup-
port? (2) Is there univentricular or biventricular involve-
ment? (3) Is signiﬁcant hypoxia present? (4) Is the in-
citing event acute or an exacerbation of chronic disease?
(5) What devices are available, and what is the level of
local expertise? Germane to the focus of this symposium,
Dr. Pagani reiterated that the most common shortcom-
ing in providing support to the left heart is the failure
to recognize signiﬁcant right heart compromise and the
need for biventricular support. Improved patient selec-
tion, patient management, and device technology have re-
duced post–left ventricular assist device (LVAD)–implant
need for RV assist device (RVAD) support. Still, 15%–20%
of the MCS patient population suffers from consequen-
ces of RV failure, exhibiting failure to thrive, poor func-
tional improvement, and dramatically accelerated short-
term mortality.
35
Perhaps what remains most elusive is deﬁning an end
point for MCS therapy. If the end point is recovery, then
clinicians have to be prepared to withdraw mechanical
support when recovery is not feasible. If the end point is
transplantation, then the goal of MCS is to optimize nutri-
tion and other organ function while awaiting an appro-
priate donor. The utilization of short-term percutaneous
devices as bridges to transplant provides for suboptimal
outcomes, however, and thus these devices are often
transitioned to more durable devices—a “bridge-to-bridge”
tactic.
36 Dr. Pagani presented an algorithmic approach to
right-sided circulatory failure in which, after an etiology is
determined, the extent of pulmonary failure, biventricular
involvement, and the need for short-term versus long-term
support are considered to determine the optimal MCS de-
vice. Options include percutaneous and durable devices as
wellasvenoarterial,venovenous,andrightatrium–leftatrium
extracorporeal membrane oxygenation (ECMO) conﬁgura-
tions (Fig. 3).
Devices designed for RV support. Temporary support
options (extracorporeal systems) include the Levitronix
CentriMag, Abiomed AB5000, and Berlin Pediatric Excor
VADs, which all require surgical implantation. These sys-
tems are most frequently used in postcardiotomy shock
scenarios and are less commonly employed for RV failure
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device in the United States is the Levitronix CentriMag,
which can be conﬁgured to provide full or partial support
for the RV, the LV, or both. This device is a continuous-
ﬂow centrifugal pump with an internal rotor that is mag-
netically levitated with no internal bearings, allowing for
low levels of hemolysis. It provides 6–9 L/min of support,
is durable, can be used for ECMO circuits, and is ap-
proved by the US Food and Drug Administration (FDA)
for RVAD use for up to 30 days.
37 In ideal cases, patients
can ambulate, allowing for optimization and recovery. Un-
fortunately, however, rates of stroke, bleeding, and infec-
tion remain very high. A new percutaneous option is of-
fered by the Abiomed Impella RP RVAD, which has yet to
be approved by the FDA. It is a centrifugal pump with an
axial design and a mechanical pivot that is inserted
percutaneously through the femoral vein and positioned
in the pulmonary artery. Blood from the inferior vena cava
is aspirated and expelled into the pulmonary artery at a
maximum rate of 4.4 L/min. It is currently under investi-
gation for post–LVAD implantation and postcardiotomy
RHF in the Recover Right trial (http://clinical trials.gov,
NCT01777607). Dr. Pagani pointed out, however, that de-
spite consistent improvement in hemodynamics, percuta-
neous support devices have failed to demonstrate a sur-
vival beneﬁt in several clinical trials.
38-42 This may be due
to the fact that RV or LV dysfunction did not have sufﬁ-
cient time to resolve, and thus temporary support did not
sufﬁce or translate to a survival beneﬁt.
Durable devices for RV support include the Thoratec
IVAD, the Thoratec pVAD, and the SynCardia Cardio-
West Total Artiﬁcial Heart (TAH). The 2 Thoratec VADs
represent ﬂexible, pneumatically actuated systems that
use older technology and are FDA approved as bridges
to recovery or transplantation. Although the pneumatic
systems are large and cumbersome and require tether-
ing to a portable drive console, these devices allow for pa-
tients to be discharged to home. The SynCardia TAH is
FDA approved for bridge to transplantation for severe bi-
ventricular failure, intractable arrhythmias, unusual anat-
omy, or complicated reoperation.
43 Data from the Inter-
agency Registry for Mechanically Assisted Circulatory
Support (INTERMACS) show TAHs confer a higher 3-
and 6-month survival compared to biventricular assist de-
vices (85% vs 70% and 68% vs 62%, respectively).
44 New
opportunities to utilize continuous-ﬂow pump technology
for a TAH system are on the horizon. This technology
results in pulseless circulation, can be used for adult con-
genital heart disease, and allows for dynamic responses
to physiologic demand. Dr. Frazier
45 was the ﬁrst to im-
plant 2 modiﬁed Thoratec HeartMate II devices to provide
for a continuous-ﬂow total heart replacement in the United
States.
Exciting prospects exist for the implementation of du-
rable devices to provide right-sided support. The HeartWare
HVAD is a continuous-ﬂow rotary pump with centrifugal
ﬂow designed for LV assist that has also been used for
RV and biventricular circulatory support,
46,47 although it
Figure 3. Algorithmic approach to device consideration for right-sided circulatory support in the setting of right-sided circulatory
failure. ECMO: extracorporeal membrane oxygenation; LA: left atrial; LV: left ventricular; RA: right atrial; RV: right ventricular; VA:
venoarterial; VV: venovenous; 2°: second-degree. Figure provided by Dr. Francis Pagani and reproduced with his permission.
722 | Transplantation in end-stage PH Lalais not approved for these indications. The challenge of
using LVAD technology for RV support, however, lies in
the required modiﬁcation of current devices to cater to
RV morphology and physiology. The inlet cannula, for ex-
ample, is designed for the thickness of the LV and is too
long for the thin RV free wall. Differences in afterload
may also require the pump to run outside of its normal
operating range. Dr. Krabatsch and his group
47 in Berlin
were the ﬁrst to report a modiﬁed approach to biven-
tricular support using the HVAD technology, in 17 pa-
tients for whom 30-day survival was 82% (Fig. 4). As sys-
tems shrink in size, applications for biventricular support
become more promising. The HeartWare Miniaturized
Ventricular Assist Device (MVAD) centrifugal pump will
provide up to 6 L of ﬂow and will enable minimally inva-
sive surgical approaches. In fact, the multicenter trial to
study this technology (http://clinical trials.gov, NCT01831544)
may include an arm to evaluate efﬁcacy in providing bi-
ventricular support.
Translating the concept of modiﬁed use of LVAD tech-
nology to the interventional laboratory, Dr. Navin Kapur
and colleagues
48 reported a multicenter experience of a per-
cutaneous centrifugal-ﬂow RVAD (TandemHeart, Cardiac-
Assist, Pittsburgh) as a part of a registry in 46 patients.
Their ﬁndings suggest that this technology is feasible
in a variety of acute clinical care settings and warrants
prospective evaluation.
In closing, Dr. Pagani touched on the provocative con-
sideration of MCS for RHF in the setting of PVD. A
primary concern for RVAD support in this setting is that
the generation of high ﬂows across a diseased circulation
with high resistance may increase PA pressures and elicit
pulmonary hemorrhage.
49 Axial and centrifugal pumps, in
particular, are exquisitely sensitive to high afterload, which
may proscribe their application for this patient popula-
tion. Partial-assist devices, such as the CircuLite device or
the Impella RP RVAD, may provide adequate hemody-
namic support without overwhelming the pulmonary
circulation; however, their use in patients with end-stage
PVD remains speculative. Where RVAD technology may
play a pivotal role is for the select patient with controlled
PH and residual RV failure, as a bridge to recovery or
transplantation. Because of the high economic burden and
unclear outcomes that these potential treatments pose,
employment of RVAD technology in patients with RHF
and PVD should be considered in the context of a clini-
cal trial.
GROWING NEW LUNGS: DREAM OR REALITY?
Current active clinical trials examining the role of stem
cell therapeutics in lung disease are devoted to the study
of IPF and COPD but not PH. In the fourth and ﬁnal
talk, delivered by Dr. Edward Ingenito, the focus returned
to evolving cell-based therapy as it may apply to regener-
ation of lung tissue and parenchyma in advanced disease.
He shared an ongoing investigation within the context of
emphysema and hypothesized how this developing ther-
apy may be applied to the ﬁeld of PVD.
Although considerable progress has been made in med-
ical therapy for PH, when compared to other advanced
lung diseases, including asthma, emphysema, and IPF,
limited treatments exist outside of transplantation for any
end-stage pulmonary pathology. The umbrella of restora-
tive therapy to reinstate the structure and function of
damaged tissue encompasses adaptive remodeling (lung
volume reduction surgery for emphysema or myectomy
for cardiomyopathy), orthotopic tissue transplant, and re-
generative therapy. The latter involves gene therapy, phar-
macologic approaches, and cell therapeutics to improve
function, with an increasing emphasis placed on stem cell
therapy over the past decade.Emphysema involves the non-
ﬁbrotic progressive destruction of lung parenchyma distal
to the terminal bronchi, resulting in the loss of tissue
and lung hyperexpansion. A design for regenerative stem
cell therapy in this model requires a system for target-
ing the alveolar compartment and an adaptive cell that
retains its regenerative capacity in vivo. Lung structure is
comprised of a rich capillary network for gas exchange,
a strong, resilient extracellular matrix, and epithelial cells
to ensure an intact surface. Therefore, a lineage-committed
Figure 4. Reduction of the effective length of the inﬂow can-
nula with 2 dacron velour–covered 5-mm silicon suture rings.
Copyright 2011, American Heart Association, Inc.; reproduced
with permission from Figure 3 of Krabatsch et al.
47
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rebuild structure and function.
Dr. Ingenito’s group
50 developed progenitor cells from
explanted intact lung tissue, allowing them to retain their
cellular replicative and regenerative potency. Lung-derived
mesenchymal cells (LMSCs) play a critical role in activat-
ing resident cells to heal tissue. Unlike BMSCs or ﬁbro-
blasts, LMSCs are highly clonogenic and do not require
input from adjacent cells to survive. These cells are also
capable of secreting key components of lung basement
membrane, which are important not only for developing
the extracellular matrix in emphysema but also for ex-
panding the vasculature in disease states such as PH.
When LMSCs are added to a basement membrane–like
environment, they spontaneously organize into alveolar
structures, secreting potent growth factors and mature
elastogenic ﬁbers. Although multiple factors block the
sustained activation and survival of these cells on both
the endovascular and the endobronchial sides, the crea-
tion of a scaffold via cross-linking surface integrins was
discovered to mediate this process. The scaffold stimu-
lates activation of focal adhesion kinase and integrin link
kinase, which permit survival and retained reparative ca-
pacity. Ovine models were used in Dr. Ingenito’s labo-
ratory to demonstrate successful in vivo delivery of func-
tional reparative cells to target sites in the lung by way
of this engineered scaffold system.
50 Elastase was used
to induce unilateral emphysema in 4 sheep lungs. Healthy
tissue was biopsied and used to generate autologous
LMSCs, which were then injected into both diseased
emphysematous lung tissue and healthy lung tissue to
ensure that no damage ensued upon engraftment. The
Figure 5. Design and testing of biological scaffolds for delivering reparative cells to target sites in the lung. Quantitative perfusion
scans and computed tomography images were used to show elastase-induced emphysematous (emphy) and healthy lung before
treatment, immediately after treatment, and 4 weeks after treatment (post tx) with lung-derived mesenchymal stem cells (LMSCs).
Copyright 2009 John Wiley & Sons, Ltd.; reproduced with permission from Figure 7 of Ingenito et al.
50
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ﬁbronectin-vitronectin hydrogel, or scaffold, was well tol-
erated clinically. Computed tomography and nuclear
scintigraphy were used to assess tissue mass and lung
perfusion, respectively, indicating emphysema test sites.
At 4 weeks, cell proliferation and improvement in struc-
ture were observed at diseased locations, with no pa-
thology at healthy treated sites (Fig. 5). This model was
next tested in a randomized controlled trial, where 10 dis-
eased sheep underwent implantation of scaffold alone
(5) or scaffold containing LMSCs (5). At 4-week follow up,
LMSC transplantation was well tolerated and resulted in
increased tissue mass and perfusion, compared to the con-
trol treatment. Increased cell proliferation and extracellu-
lar matrix were conﬁrmed on histology. The authors
50 con-
cluded from these studies that autologous LMSC trans-
plantation is feasible and safe and that it may promote
regeneration via secretion of growth factors, elastogenesis,
and alveologenesis. The FDA has granted permission to
initiate a phase 1 clinical trial using this therapy for ad-
vanced emphysematous disease for lung transplant candi-
dates on an active waiting list. This experimental model
has not been tested in PVD. However, in closing, Dr. In-
genito proposed a rationale for why such a construct may
indeed be restorative in the setting of PVD, namely, that
activated LMSCs secrete angiogenic growth factors that
could potentially contribute to the regrowth of the compro-
mised vasculature. The ﬁeld of cellular therapeutics is rap-
idly evolving, with some studies in humans, and may have
broader clinical applications with time, including the dis-
ease state of PH.
CONCLUSIONS
Although signiﬁcant progress has been made in the un-
derstanding of RV-pulmonary vascular pathophysiology,
deﬁnitive therapeutic options outside of transplantation
are limited for the treatment of end-stage disease. The
International Right Heart Summit was a unique forum
that enabled cross talk among world-renowned physician-
scientists to advance current thinking and consider novel
approaches to the treatment of RHF. In this context, cur-
rently available and developing technologies for salvag-
ing the RV were reviewed. At one end of the spectrum,
models of stem cell proliferation and utilization to repair
and regenerate tissue provide for an exciting therapeutic
paradigm in the potential treatment of PVD and RV dys-
function. At the other end, advances in the ﬁeld of MCS
may allow for miniaturized temporary and durable as-
sist devices uniquely designed for right heart support as
bridges to recovery and/or transplantation. Future work
and clinical trials are ongoing to study the clinical appli-
cation of these wide-ranging novel approaches to the pa-
tient with end-stage right heart disease.
Source of Support: Nil.
Conﬂict of Interest: None declared.
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